Mitsubishi UFJ Asset Management UK Ltd. Purchases New Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,000 shares of the life sciences company’s stock, valued at approximately $204,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IART. KBC Group NV increased its position in Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after buying an additional 1,120 shares during the period. Northwest Investment Counselors LLC bought a new position in Integra LifeSciences during the 3rd quarter worth approximately $73,000. Canada Pension Plan Investment Board acquired a new stake in Integra LifeSciences during the 2nd quarter worth approximately $114,000. Centiva Capital LP acquired a new stake in Integra LifeSciences during the 3rd quarter worth approximately $192,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Integra LifeSciences in the third quarter valued at approximately $198,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $25.12 on Wednesday. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -279.08, a price-to-earnings-growth ratio of 0.80 and a beta of 1.16. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $45.42. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a 50 day moving average of $23.18 and a 200-day moving average of $22.35.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter last year, the firm posted $0.76 EPS. Integra LifeSciences’s revenue was down .4% compared to the same quarter last year. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Bank of America cut their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Finally, Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and a consensus price target of $23.00.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.